GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Net Current Asset Value

SMTI (Sanara MedTech) Net Current Asset Value : $-1.76 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Sanara MedTech's net current asset value per share for the quarter that ended in Dec. 2024 was $-1.76.

The historical rank and industry rank for Sanara MedTech's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sanara MedTech was 383.85. The lowest was 12.01. And the median was 267.65.

SMTI's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.75
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Sanara MedTech Net Current Asset Value Historical Data

The historical data trend for Sanara MedTech's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Net Current Asset Value Chart

Sanara MedTech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 2.46 0.17 -1.18 -1.76

Sanara MedTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -1.21 -1.24 -1.93 -1.76

Competitive Comparison of Sanara MedTech's Net Current Asset Value

For the Medical Instruments & Supplies subindustry, Sanara MedTech's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanara MedTech's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's Price-to-Net-Current-Asset-Value falls into.


;
;

Sanara MedTech Net Current Asset Value Calculation

Sanara MedTech's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(33.306-49.18--0.492-0)/8.754
=-1.76

Sanara MedTech's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(33.306-49.18--0.492-0)/8.754
=-1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanara MedTech  (NAS:SMTI) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Sanara MedTech Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanara MedTech Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077